Authors: Falutz J, Allas S, Blot-Chabaud M, et al.
-15.2% mean reduction in visceral adipose tissue (VAT) at week 26
In a randomized, double-blind, multicenter trial, 412 patients with HIV-associated abdominal fat accumulation received daily subcutaneous injections of tesamorelin (2 mg) or placebo for 26 weeks. Visceral adipose tissue (VAT) was measured by computed tomography. Tesamorelin induced a significant 15.2% reduction in visceral fat volume compared with a 1.0% increase with placebo (P<0.001), while maintaining subcutaneous adipose integrity.
Pivotal phase 3 clinical trial demonstrating that the stabilized GHRH analog tesamorelin selectively reduces pathological visceral abdominal adipose tissue by 15.2% without subcutaneous fat wasting.
* Educational commentary prepared by Peptide Health Digest editors to provide context on study methodology.
Falutz J, Allas S, Blot-Chabaud M, et al.
This study record was compiled from public biomedical repositories for educational and informational reference. Peptide Health Digest does not claim authorship of the original investigation.
